Product Images Donepezil Hydrochloride

Not-Available.*

This appears to be a table with data about a medical trial. It includes information about different treatment groups (including a placebo group), the dosage used, and the change in ADAS cog (a measure of cognitive impairment) for each group. The table also has a graph showing the change from baseline for the different groups. However, the text is largely incomprehensible and appears to be the result of errors. Therefore, a more specific description cannot be provided.*

This appears to be a chart or table showing the percentage of patients who have taken different dosages of Donepezil Hydrochloride and a placebo, along with their corresponding improvement ratings based on the CIBIC-plus Rating scale. The table shows the number of patients who took Donepezil Hydrochloride at 10mg/day, 5mg/day, and a placebo. The improvement ratings range from "Markedly Improved" to "Markedly Worse."*

The text appears to be a graph or chart showing the ADAS-cog change from baseline for different drug treatments over a period of 15 weeks. Without the visual aid, it is not possible to provide a more detailed description.*

This seems to be a graph or table representing the cumulative percentage of patients along with the percentage of change in ADAS cog for different treatment groups. The treatment groups appear to include Donepezil Hydrochloride at 10mg and 5mg doses, as well as a Placebo group. The change in ADAS cog ranges from 0-72% across the different groups. The text at the bottom may represent a scale for the graph, showing changes from baseline.*

This appears to be a graph displaying the percentage of patients who took different doses of Donepezil Hydrochloride (at either 10 mg/day or 5mg/day) or a placebo, showing the level of improvement in their condition as either markedly improved, moderately improved, minimally improved, no change, minimally worse, moderately worse, or markedly worse. The data is captured in a graph with a CIBIC-plus rating.*

This is a graph that shows the change from baseline in the SIB (Severe Impairment Battery) score after 3 months of drug treatment with Donepezil Hydrochloride 10 mg/day compared to placebo. The graph shows the mean score and standard error for both treatments. There is no additional information available.*

The text shows a chart that displays the cumulative percentage of patients who have been treated with either Donepezil Hydrochloride 10 mg/day or Placebo, and their SIB (Severe Impairment Battery) change from baseline over a period of time. Unfortunately, there is not enough information to determine the efficacy or results of the treatments.*

This is a graph displaying change from baseline in the ADCS-ADL score after administration of either placebo or donepezil hydrochloride tablets at a dose of 10 mg per day over 3 months. The x-axis indicates the months of drug treatment, and the y-axis shows the mean score along with the standard error. It appears that there is a clinical improvement with donepezil treatment and a decline in the placebo group over time.*

The text indicates a graph showing the cumulative percentage of patients who have taken Donepezil Hydrochloride 1 mg/day versus Placebo medication. The graph shows a comparison of the ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) Change from Baseline. The Donepezil Hydrochloride 1 mg/day shows a gradual increase in the cumulative percentage of patients, while Placebo shows a slight increase with a plateau. There is no information available about the effectiveness of the medication or the duration of the study.*

The text represents a clinical trial comparing the effects of two different dosages of donepezil hydrochloride on a certain condition. The dosage of 23 mg per day showed a 3% improvement compared to the 10 mg per day dosage. The trial lasted for 18 weeks.*

This appears to be a graph or chart showing the cumulative percentage of patients and their SIB (Severe Impairment Battery) change from baseline, comparing the drugs Donepezil Hydrochloride 10mg and 23mg. However, it is difficult to accurately interpret or provide further information without additional context or the visual of the chart.*

Each tablet of Donepezil Hydrochloride, USP contains 10mg of donepezil. Dosage and use information is available in the accompanying prescribing information. Store in a tightly closed container as per the USP at 20°C to 25°C, with excursions permitted between 15°C to 30°C. This medication is only available through a prescription and its Patient Information must be dispensed to each patient by the pharmacist. A batch of 1000 tablets are provided in this package, which has been manufactured by SciGen Pharmaceuticals, Inc. located in Hauppauge, NY 11788.*

NDC 50228-140-30 is the product code for Sz Donepezil's Hydrochloride tablets. This medication is used to treat certain mental disorders. It is important to read the accompanying prescribing information before use. The tablets should be stored at a controlled room temperature between 20-25°C (59-86°F) and must be dispensed to patients in a tight container with child-resistant closure. These tablets are manufactured by ScieGen Pharmaceuticals, Inc. and the packaging contains 30 tablets. The information on patient use is not available.*

This is a medication called Donepezil Hydrochloride Tablets, USP. Each tablet contains 5 g of donepezil hydrochloride. The dosage and usage information can be found in the accompanying prescribing information. The medication should be stored in a tight container at a temperature of 20° to 25°C, with permitted excursions to 15° to 30°C. The medication is dispensed by pharmacists and comes with accompanying patient information. The manufacturer is Scieen Pharmaceuticals, Inc. located in Hauppauge, NY 11788.*

This is a medication with the NDC code 50228-139-30, whose active ingredient is Donepezil in Hydrochloride form. The prescription medication comes in the form of tablets, and the recommended dosage and usage are mentioned in the accompanying prescribing information. The medication is recommended to be dispensed in a tightly closed container with child-resistant closure, and the recommended storage temperature is between 15°C to 30°C (59°F to 86°F). The medication is manufactured by ScieGen Pharmaceuticals Inc., located in Hauppauge, NY 11788.*